Immunotherapies
have evolved
Harnessing more of the immune system for better cancer outcomes
Latest News

Fascinating discovery led by Michael Chopin @WEHI_research
Differential role of PRC2 complex in myeloid cell development. Michael is emerging as a national leader in myeloid/DC research. Very exciting area 👏
https://www.science.org/doi/10.1126/sciimmunol.abf7268

@Daily_Experts Blood Cancer Awareness Month. Our @MonashBDI lab and @oNKo_innate are working hard on understanding NK cell biology to reveal drug targets to boost NK cell immunity to blood cancers. Tumour engager biologics and CAR cell therapies are having a BIG impact but still lots to do.....

We’re delighted to receive $16.12 million through the State Government’s Victorian Higher Education State Investment Fund to enhance smart manufacturing, and #research and development commercialisation at Monash. 🧑‍🔬 Learn more: http://mona.sh/VA4w30rSINJ
#ChangeIt

Load More...
 
Discover oNKo-innate
With our deep understanding of Natural Killer (NK) cells, we aim to be the first to master NK cell biology and therapeutically harness the cancer-fighting abilities of these remarkable white blood cells.
Learn more
OUR APPROACH
Using powerful genomic approaches, we screen primary immune cells and cancer cells to understand their interaction within a tumor.
Learn more
lab1-webRes
o o
o
THE TEAM
We are driven by the challenge of engaging the immune system to fight cancer, and focused on delivering the first truly effective NK cell immunotherapies.
Find out who we are